First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer

Gastric Cancer

Volumn 15, Issue 1, 2012, Pages 21-26

  Iwasa, Satoru ^a   Nakajima, Takako Eguchi ^a   Nakamura, Kenichi ^a   Takashima, Atsuo ^a   Kato, Ken ^a   Hamaguchi, Tetsuya ^a   Yamada, Yasuhide ^a   Shimada, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Ascites; Gastric cancer; Oral intake; Peritoneal metastasis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; METHOTREXATE; MITOMYCIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASCITES; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; LEUKOCYTE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERITONEUM METASTASIS; PRIORITY JOURNAL; SEPTIC SHOCK; SIDE EFFECT; STOMACH ADENOCARCINOMA; SURVIVAL TIME; SYSTEMIC THERAPY; THROMBOCYTE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STOMACH NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861528822     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0056-y     Document Type: Article

References (20)

1. Dupont JB Jr, Lee JR, Burton GR, Cohn I Jr. Adenocarcinoma of the stomach: review of 1497 cases. Cancer. 1987;41:941-7.
2. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240:808-16. (Pubitemid 39425773)
3. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236-42. (Pubitemid 30088655)
4. Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg. 2000;87:353-7. (Pubitemid 30156364)
5. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
6. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36-46.
7. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized phase III noninferiority trial. Ann Oncol. 2009;20:666-73.
8. Lokich J, Bothe A, Fine N, Perri J. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer. 1981;48:2565-8. (Pubitemid 12194243)
9. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063-9.
10. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Takiuchi H, et al. Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). J Clin Oncol. 2009;27:15s (Suppl; Abstr 4545).
11. Yamao T, Shimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I, et al. Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol. 2004;34:316-22. (Pubitemid 43118050)
12. Yumiba T, Oba K, Iishi H, Narahara H, Morimoto T, Nakamura M, et al. A multicenter phase II trial of paclitaxel for patients with ascites caused by advanced/recurrent gastric cancer, a new concept of clinical benefit response for non-measurable type of gastric cancer. 2008 Gastrointestinal Cancers Symposium (Abstract 51), January 25-27, Orlando, Florida.
13. Oh SY, Kwon HC, Lee S, Lee DM, Yoo HS, Kim SH, et al. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX- 4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol. 2007;37:930-5. (Pubitemid 351176484)
14. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003;21:54-9.
15. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435-42.
16. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as firstline therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-7. (Pubitemid 46631401)
17. Emi Y, Yamamoto M, Takahashi I, Orita H, Kakeji Y, Kohnoe S, et al. Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer. Surg Today. 2008;38:1013-20.
18. Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K, et al. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol. 2006;12:1412-5.
19. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol. 2001;12:1133-7. (Pubitemid 32834495)
20. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol. 1998;21:416-9. (Pubitemid 28366916)